Active	Status	Sponsor type	Region	Phase	Filter
6 Active 15 Inactive 21 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vichinsky, Elliott
THRIVE-132, NCT04927247: A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises	Terminated	3	72	Europe, US, RoW	Inclacumab, Placebo	Pfizer	Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease	11/23	11/23
PB04-001, NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia	Recruiting	1/2	36	Canada, US	Benserazide Only Product	Phoenicia BioScience, National Heart, Lung, and Blood Institute (NHLBI)	Beta Thalassemia Intermedia, Sickle Cell Disease	12/24	02/25
Kuo, Kevin HM
PB04-001, NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia	Recruiting	1/2	36	Canada, US	Benserazide Only Product	Phoenicia BioScience, National Heart, Lung, and Blood Institute (NHLBI)	Beta Thalassemia Intermedia, Sickle Cell Disease	12/24	02/25
TICATS, NCT04291352: Thalassemic Iron Overload Cardiomyopathy is Ameliorated by Taurine Supplementation	Recruiting	N/A	60	Canada	Taurine, Placebo	University Health Network, Toronto	Thalassemia Major	10/24	10/25
Singer, Sylvia T
PB04-001, NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia	Recruiting	1/2	36	Canada, US	Benserazide Only Product	Phoenicia BioScience, National Heart, Lung, and Blood Institute (NHLBI)	Beta Thalassemia Intermedia, Sickle Cell Disease	12/24	02/25
Lal, Ashtosh
PB04-001, NCT04432623: The BENeFiTS Trial in Beta Thalassemia Intermedia	Recruiting	1/2	36	Canada, US	Benserazide Only Product	Phoenicia BioScience, National Heart, Lung, and Blood Institute (NHLBI)	Beta Thalassemia Intermedia, Sickle Cell Disease	12/24	02/25